A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
This is a pilot study of crizotinib in patients with c-MET positive gastric adenocarcinoma.
c-MET Positive Gastric Cancer
DRUG: crizotinib
progression-free survival, expected average of 24 weeks
overall response rate, up too 100 weeks|overall survival, up too 100 weeks|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, up too 100 weeks
This is a pilot study of crizotinib in patients with c-MET positive gastric adenocarcinoma.